- Molecular NameDoxycycline
- SynonymDoxcycline anhydrous; Doxycycline Hyclate; Doxycycline Monohydrate; Doxytetracycline
- Weight444.44
- Drugbank_IDDB00254
- ACS_NO564-25-0
- Show 3D model
- LogP (experiment)-0.02
- LogP (predicted, AB/LogP v2.0)-0.42
- pka3.5, 7.7, 9.5
- LogD (pH=7, predicted)-3.16
- Solubility (experiment)0.63 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.58
- LogSw (predicted, AB/LogsW2.0)1.04
- Sw (mg/ml) (predicted, ACD/Labs)0.75
- No.of HBond Donors7
- No.of HBond Acceptors10
- No.of Rotatable Bonds2
- TPSA181.62
- StatusFDA approved
- Administrationral, buccal, iv, im
- PharmacologyA member of the tetracycline antibiotics group and is commonly used to treat a variety of infections.
- Absorption_valueN/A
- Absorption (description)Readily and almost completely absorbed after oral administration
- Caco_2N/A
- Bioavailability93.0
- Protein binding88.0
- Volume of distribution (VD)0.75 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt does not appear to be significantly metabolised.
- Half life16 h
- ExcretionAbout 40% of a dose is excreted in the urine unchanged in 72 h (about 24% in the first 24 h).
- Urinary Excretion41
- Clerance0.53 ml/min/kg
- ToxicityAnorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region. skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia.
- LD50 (rat)LD50=262 mg/kg(i.p. in rat)
- LD50 (mouse)N/A